key: cord-0270595-rjse7bkh
authors: Rao, S.; Hurst, J. H.; Zhao, C.; Goldstein, B. A.; Thomas, L.; Lang, J. E.; Kelly, M. S.
title: Asthma and the Risk of SARS-CoV-2 Infection Among Children and Adolescents
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.20.21260871
sha: 90e42e9586d744cc2e01a7decb6afb0958f22f2a
doc_id: 270595
cord_uid: rjse7bkh

Importance: More than 4 million SARS-COV-2 infections have occurred among children and adolescents in the United States. Risk factors for SARS-CoV-2 infection among children remain poorly defined. Objective: To evaluate the association between asthma and the risk of SARS-CoV-2 infection among children. Design: Retrospective cohort study Setting: A large, integrated health system in central North Carolina. Participants: Children 5 to 17 years of age with a Durham County address and at least one health care encounter in the Duke University Health System between March 1, 2017, and February 28, 2020. Exposure: Diagnosis of asthma Main Outcomes and Measures: The primary outcome was SARS-CoV-2 infection identified by PCR testing of a respiratory sample collected between March 1, 2020, and October 31, 2020. We matched children with asthma 1:1 to children without asthma using propensity scores and used Poisson regression to evaluate the association between asthma and the risk of SARS-CoV-2 infection. We assessed for effect modification of this association by inhaled corticosteroid prescription and comorbid atopic diseases. Results: Of 49,455 children, 6,515 (13%) met criteria for a diagnosis of asthma; all children with asthma were matched to a control child without asthma for a final cohort of 13,030 children. Median (interquartile range) age was 11.0 (8.0, 14.0) years, 56% were male, and 78% were non-White. A diagnosis of asthma was associated with a decreased risk of SARS-CoV-2 infection [risk ratio (RR): 0.67, 95% confidence interval (CI): 0.49-0.92]. This association tended to be stronger in children with asthma who were prescribed inhaled corticosteroids (RR: 0.60, 95% CI: 0.38-0.94) or who had comorbid atopic diseases (RR: 0.59, 95% CI: 0.39-0.88). Of the 66 children with asthma who developed SARS-CoV-2 infection, none required hospitalization for COVID-19. Conclusions and Relevance: Children with asthma had a lower risk of SARS-CoV-2 infection, particularly children prescribed an inhaled corticosteroid or with comorbid atopic diseases. Further studies are needed to explore the complex relationship between asthma, inhaled corticosteroids, and SARS-CoV-2.

INTRODUCTION the extent to which use of inhaled corticosteroids (ICS) and the presence of comorbid atopic diseases modified the association between asthma and the risk of SARS-CoV-2 infection.

This study was conducted in the Duke University Health System (DUHS), a comprehensive medical system consisting of a large academic medical center, two community hospitals, a network of primary and urgent care clinics, and both inpatient and outpatient subspecialty services. DUHS serves as the main health care provider in Durham County, North Carolina, with an estimated 85% of Durham residents receiving care within DUHS. This study was conducted during an eight-month period from March 1, 2020 to October 31, 2020.

We identified all children 5 to 17 years of age with a Durham County address and at least one health care encounter in DUHS within the three years preceding the study period (March 1, 2017, to February 28, 2020). We classified children as having asthma if they met one of three previously validated electronic health record-based definitions during this three-year period: 1) two or more outpatient or emergency health care encounters associated with an International Classification of Diseases, Ninth/Tenth Revision (ICD-9/ICD-10) code for asthma (Supplemental Table 1 ) and an active prescription for one or more medications for asthma (Supplemental Table 2) ; 2) at least one hospital encounter associated with an ICD-9/ICD-10 for asthma and an active prescription for one of more medications for asthma; or 3) a problem list entry with an asthma-related ICD-9/ICD-10 code and an active prescription for one or more medications for asthma. 10 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

We used the Duke University School of Medicine Clinical Research Datamart to abstract patient data from electronic health records. 11 Data recorded included age, gender, race/ethnicity, insurance status, and the neighborhood deprivation index, a metric that incorporates income, education, employment, and housing quality to create scores for neighborhoods based on socioeconomic disadvantage. 12 To account for differences in health system engagement that could influence the likelihood of being tested for SARS-CoV-2 infection, we recorded if the child's pediatrician was within DUHS, if the child had a well-child visit in the two years prior to the study period, and the number of health care encounters in the one year preceding the study period. To identify a subset of children with asthma who were more likely to have an atopic asthma phenotype, we identified allergic rhinitis, atopic dermatitis, food allergies, and other comorbid atopic diseases using ICD-9/ICD-10 codes (Supplemental Table 1 ). SARS-CoV-2 infection was identified based on positive PCR testing of a respiratory sample obtained for clinical care.

We described characteristics of the study population by asthma status, by performance of SARS-COV-2 testing, and based upon the results of SARS-CoV-2 testing. We used Poisson regression with a sandwich variance estimator to evaluate associations between asthma, demographics, insurance type, health system engagement, and neighborhood characteristics with performance of SARS-CoV-2 testing. 13 We used a similar modeling approach to evaluate associations between these same factors and positive testing for SARS-CoV-2 among children who underwent one or more tests for the virus. We used logistic regression to evaluate associations between demographics, insurance type, health system engagement, and neighborhood characteristics with asthma status. The predicted covariate values from this model were then used to generate propensity scores for the probability of having asthma for all children in the dataset. We then matched each child with asthma to a single child without asthma using nearest-neighbor matching of propensity scores. Distributions of propensity scores were evaluated for balance across the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; asthma and control groups (Supplemental Figure 1) . For our primary analysis, we used Poisson regression with a sandwich variance estimator to evaluate the association between asthma status and the risk of SARS-CoV-2 infection in the propensity score-matched cohort. Finally, in a priori-specified secondary analyses, we fit modified Poisson regression models to evaluate for effect modification of the association between asthma status and SARS-CoV-2 infection by ICS prescription and comorbid atopic diseases in the propensity score-matched cohort. All statistical analyses were performed using R version 4.0.2. 14

Of 49,455 children, 6,515 (13.2%) met the definition for asthma (Figure 1) . Characteristics of the unmatched cohort by asthma status are shown in Table 1 . Compared to children without asthma, children with asthma were more likely to be male (58% vs. 50%, p<0.001), to identify as non-Hispanic Black race (55% vs. 33%, p<0.001), and to have public insurance (57% vs. 48%, p<0.001). Children with asthma were also more likely to have had a well-child visit within the prior two years (69% vs. 52%, p<0.001), had more health care encounters in the preceding one year [median (interquartile range (IQR)): 2 (1, 4) vs.

1 (0, 2), p<0.001], and were more likely to have a primary care physician in DUHS (99% vs. 97%, p<0.001). Age and neighborhood deprivation were similar among children with and without asthma.

Overall, 3,594 (7.3%) children had one or more tests for SARS-CoV-2 during the study period. Children with asthma were more likely to have been tested for SARS-CoV-2 infection than children without asthma (10.4% vs. 6.8%, p<0.001). Patient age, race/ethnicity, insurance status, and neighborhood deprivation index scores differed by SARS-CoV-2 testing status ( Table 2) . Specifically, non-Hispanic . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ;

Black race and self-pay insurance status were associated with a lower risk of being tested for SARS-CoV-2, while higher risks of being tested were observed for Hispanic ethnicity, public insurance, and higher neighborhood deprivation index scores, corresponding to higher deprivation and lower neighborhood socioeconomic status. We also observed higher levels of previous health system engagement among children who were tested for SARS-CoV-2. Compared to children who were not tested for SARS-CoV-2, tested children were more likely to have had a well-child visit in the two years preceding the study period, had more health care encounters in the year preceding the study period, and were more likely to have a primary care physician in DUHS. A total of 564 (1.1%) children tested positive for SARS-CoV-2 infection during the study period, including 66 (1.0%) children with asthma and 498 (1.2%) children without asthma. Among children tested for SARS-CoV-2 infection, non-White race, public and self-pay insurance, and higher neighborhood deprivation were associated with positive testing for SARS-CoV-2 infection ( Table 3) . One child without asthma required hospitalization for COVID-19.

We next generated propensity scores for the probability of having asthma for all children and matched each of the 6,515 children with asthma to a child without asthma using nearest-neighbor matching of propensity scores. Propensity score matching resulted in a population that was closely matched on patient characteristics ( Table 1) . Median (IQR) age was 11.0 (8.0, 14.0) years, 56% were male, and 78% were non-White. In this propensity score-matched cohort, 164 (13%) children tested positive for SARS-CoV-2 infection during the study period, including 66 (9.8%) children with asthma and 98 (16.0%) children without asthma ( Table 4) . Asthma was associated with a decreased risk of SARS-CoV-2 infection [risk ratio (RR): 0.67, 95% confidence interval (CI): 0.49-0.92]. Additionally, we found evidence of effect modification of this association by prescription of ICS and comorbid atopic disease. Specifically, children with asthma who were prescribed ICS had a lower risk of SARS-CoV-2 infection than matched control children without asthma (RR: 0.60, 95% CI: 0.38-0.94), but this association was not significant among . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; children with asthma who were not prescribed ICS (RR: 0.75, 95% CI: 0.49-1.15). Similarly, compared to matched control children without asthma, the risk of SARS-CoV-2 infection was lower among children with asthma and comorbid atopic diseases (RR: 0.59, 95% CI: 0.39-0.88), but not among children with asthma who did not have these conditions (RR: 0.83, 95% CI: 0.51-1.35).

In this population-based study of nearly 50,000 children in central North Carolina, asthma was associated with a lower risk of acquiring SARS-CoV-2 infection. This association tended to be stronger among children with comorbid atopic diseases or concomitant ICS prescription, suggesting that these factors may contribute to the reduced susceptibility of this population to SARS-CoV-2. We identified marked differences in the likelihood of children being tested for SARS-CoV-2 by sociodemographic factors.

Finally, we found no evidence that asthma predisposes children to severe COVID-19.

Few prior studies evaluated the association between asthma and susceptibility to SARS-CoV-2 infection.

In a nationwide cohort study of 219,959 adults in South Korea, adults with asthma had a slightly higher risk of testing positive for SARS-CoV-2 compared with a propensity score-matched comparison group without asthma (2.3% vs. 2.2%, respectively). 15 In a retrospective evaluation of electronic health record data from 7,256 children tested for SARS-CoV-2 in a pediatric healthcare network in the United States, 87 of 424 (21%) children who tested positive for SARS-CoV-2 had a diagnosis of asthma, in keeping with the asthma prevalence among children in this network. 16 Moreover, in a study of 135,794 patients less than 25 years of age who underwent SARS-CoV-2 testing in seven pediatric health networks in the United States, children with asthma and other previously diagnosed respiratory conditions had a lower SARS-CoV-2 positivity rate. 17 Finally, in a community-based cohort study of 382 children and adolescents with a documented SARS-CoV-2 exposure in central North Carolina, children with asthma . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

were less likely to acquire the virus. 18 In the current study, we found that asthma was associated with a 35% lower risk of SARS-CoV-2 infection among children after accounting for differences in SARS-CoV-2 testing practices. Our findings can be used by parents, educators, and health care providers to inform decisions surrounding precautions and treatments for children with asthma.

ICS are among the medications most commonly prescribed to children with asthma. 19,20 Though previous research suggests that ICS use increases the risk of non-COVID-19 respiratory tract infections, the available data indicate that these medications may not increase susceptibility to and severity of SARS-CoV-2 infection. 21 Use of ICS for pre-existing respiratory diseases was not associated with COVID-19 severity in a study of more than 8 million adults in the United Kingdom. 22 Similarly, among adults in South Korea, use of ICS was not associated with COVID-19 risk and mortality. 23 In contrast, in the OpenSAFELY Study, adults with asthma who were prescribed high-dose ICS, but not low-or mediumdose ICS, had a higher risk of death from COVID-19. 24 Finally, a retrospective analysis of 928 adult patients did not identify an association between ICS use and the likelihood of testing positive for SARS-CoV-2. 25 Our findings suggest that ICS use may contribute to the lower risk of SARS-CoV-2 infection among children with asthma and emphasize the importance of continuing these medications during the ongoing COVID-19 pandemic.

Prior epidemiological studies have failed to demonstrate an association between asthma and COVID-19 severity. In studies conducted in adult populations, asthma has generally not been identified as a risk factor for COVID-19 severity and mortality. 5, [26] [27] [28] [29] [30] [31] Similarly, studies of children hospitalized for COVID-19 have not identified a consistent association between asthma and COVID-19 severity. Among 222 children and adolescents hospitalized with COVID-19 in the United States, 13.5% had a prior diagnosis of asthma -only slightly higher than the estimated national prevalence of asthma among children (8-10%). 32 In a study of 177 children with SARS-CoV-2 infection in the Washington, D.C. metro area, asthma was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; not more common among children admitted to the hospital than among non-hospitalized children. 33, 34 Similarly, in a study of 46 children hospitalized for SARS-CoV-2 infection in New York, asthma was not associated with a requirement for intensive care. 35 Finally, an electronic health record-based analysis of children undergoing SARS-CoV-2 testing at Children's Hospital of Philadelphia facilities found that asthma was associated with a lower odds of hospitalization for COVID-19. 36 In our cohort, none of the children and adolescents with asthma who were diagnosed with SARS-CoV-2 infection required hospitalization for COVID-19. Taken together, these data suggest that asthma is not associated with worse outcomes among children and adolescents with SARS-CoV-2 infection.

There are several potential mechanisms by which asthma may reduce the SARS-CoV-2 infection risk.

SARS-CoV-2 entry is mediated by the cell surface proteins angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), both of which have been demonstrated to be expressed at lower levels in individuals with asthma compared to those without asthma, though the data are conflicting regarding the levels of ACE2 and TMPRSS2 expression associated with different asthma endotypes. [37] [38] [39] [40] [41] Atopic asthma is a common endotype among children and adolescents, and is associated with excessive T-helper type-2 (Th2) responses, 42, 43 which have been associated with lower expression of ACE2 and TMPRSS2. 44,45 Previous research also suggested potential mechanisms by which ICS could influence SARS-CoV-2 susceptibility. In a study of adults with chronic obstructive pulmonary disease, treatment with ICS was associated with reduced ACE2 expression, and this effect appeared to be mediated through suppression of type I interferon. 46 Further, the ICS ciclesonide has been shown to dampen host inflammatory responses and reduce in vitro replication of SARS-CoV-2 and other human coronaviruses. 47 Finally, the risk of SARS-CoV-2 infection might be lower among children and adolescents because of differences in behavior and risk mitigation strategies. In particular, children with asthma and other chronic respiratory diseases could have less exposure to SARS-CoV-2 than children without these chronic . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

conditions because of differences in perceived risk of severe COVID-19 and infection prevention or shielding practices.

The availability of SARS-CoV-2 testing to children during the COVID-19 pandemic has been influenced by national and local policies, testing availability, and our evolving understanding of the virus. Thus, the factors influencing the likelihood of being tested for SARS-CoV-2 have important implications for understanding the epidemiology of the virus and for identifying barriers to accessing health services. We found that children who identified as Hispanic ethnicity were tested at a higher rate than white children and children from other racial minority groups, but Hispanic children still had a far higher test positivity rate (32%) than other groups, highlighting the extent to which the Latinx community has been disproportionately affected by the COVID-19 pandemic in central North Carolina. We also observed that individuals with disadvantaged living conditions were tested at a higher rate and had a higher test positivity rate than individuals who lived in neighborhoods with higher socioeconomic status. Consistent with this finding, a study of children presenting for drive-up testing at an academic medical center reported that families in the highest income quartile based on census block group estimates tested positive at a lower rate that those from lower income quartiles. 48 Children with public insurance were both more likely to be tested for SARS-CoV-2 and had a higher SARS-CoV-2 positivity rate than children with private insurance. Taken together, these findings highlight significant disparities in SARS-CoV-2 testing accessibility and disease burden among children in central North Carolina by race/ethnicity and socioeconomic status.

Our study has several strengths and limitations. First, our cohort included more than 6,000 children with a current asthma diagnosis and active prescriptions for controller medications. While this stringent definition enabled us to have substantial confidence in the diagnosis in children classified as having asthma, children with mild asthma or who did not have active prescriptions for controller medications . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

were likely misclassified as not having asthma. We relied upon SARS-CoV-2 test results from within the health care system, and therefore could not account for SARS-CoV-2 testing that may have been performed at other sites. To minimize this possibility, we focused on children who reside in Durham County, for which DUHS provides the vast majority of primary and specialty pediatric services. We assumed that children who were not tested for SARS-CoV-2 did not have the virus; due to limited testing availability and asymptomatic infections, it is likely that some SARS-CoV-2 infections were not identified. We used propensity score matching to account for confounding in demographics associated with asthma and SARS-CoV-2. Finally, we were unable to account for differences in infection prevention and shielding behaviors that may have existed between asthmatic children and children without asthma.

In summary, despite the continued general precaution regarding asthma and COVID-19, we found no evidence that asthma predisposes children to SARS-CoV-2 infection or severe illness from COVID-19.

We strongly recommend that children with asthma continue their treatment and asthma action plans during the ongoing COVID-19 pandemic, especially if these plans include ICS. Further research is needed to evaluate the complex relationships that exist between asthma, ICS, and SARS-CoV-2.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; Table 4 . Associations between asthma status and SARS-CoV-2 infection, propensity score-matched cohort . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ;

An interactive web-based dashboard to track COVID-19 in real time

The Burden of Pediatric Asthma

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID 19

Development of an electronic health records datamart to support clinical and population health research

Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. RTI International, Agency for Healthcare Research and Quality

A Modified Poisson Regression Approach to Prospective Studies with Binary Data

R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing

Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study

The Epidemiology of SARS-CoV-2 in a Pediatric Healthcare Network in the United States

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

Impact of COVID-19 on patients with asthma. The international journal of tuberculosis and lung disease : the official journal of the International Union against

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Severe Coronavirus Disease-2019 in Children and Young Adults in the

Changing trends in asthma prevalence among children

Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19

Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium

Relationship to Demographic Features and Corticosteroids

The allergic asthma phenotype